The launch of SCIZYS by Lumito will be slightly delayed
As previously communicated, Lumito's ambition and plan has been to offer product for researchers use only by the end of 2022. Employees and production partners have together set the plan and worked hard and focused on fulfilling the ambition, which has been deemed fully realistic until now. Lumito therefore wishes to inform that the launch […]
Testing the Lumito scanner with the final product design
Lumito's research and development team has attended the operational testing of the company's scanner with the final product design at the Swedish partner, Optronics Partner pr. Since a few months ago Lumito is in the commercialization phase with production as an area of focus. The purpose of the briefing was to test all the scanner's functions […]
Lumito – Associated Member of PathLAKE and part of the Consortium’s highly valuable network
Lumito's application for Associate Membership of the PathLAKE Consortium has been approved. The PathLAKE Consortium is a network of leading NHS Trusts and UK universities who, in collaboration with industrial partners, are at the forefront of innovation in digital pathology. The Consortium's work includes AI-driven diagnostics to increase the efficiency and effectiveness of pathology reporting […]
Lumito publishes Quarterly Report 2, 2022
First half of the year 1 January–30 June 2022 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -13,610 (-13,444). Basic and diluted earnings per share amounted to SEK -0.09 (-0.15) Cash flow from operating activities after change in working capital amounted to KSEK -14,636 (-12,883). Cash and cash equivalents amounted […]
Preliminary study to detect immune complex and complement deposits in renal biopsies initiated with the University Hospitals Coventry and Warwickshire in the UK
A proof of concept-study to explore the potential of Lumito's UCNP to detect immune complex and complement deposits in renal biopsies has been initiated in collaboration with University Hospitals Coventry and Warwickshire NHS Trust in the UK and a research team led by Dr. Kishore Gopalakrishnan. Obtaining a renal biopsy is an invasive procedure […]
Booth at the European Congress of Pathology – a step towards commercialisation
For the first time ever, Lumito will have its own booth at a pathology congress. Booth number 79 has been booked for the European Congress of Pathology, which will take place in Basel from 3-7 September. "We are now ready to expose our product at one of Europe's busiest trade fairs for pathologists and other […]
Letter of Intent signed with Kaivogen Oy to produce Lumito’s complete reagent kits
Lumito AB and the Finnish company Kaivogen Oy have signed a Letter of Intent to produce Lumito's immunohistochemistry reagent kit, which is part of the company's complete product offering in digital tissue analysis. The ambition is to launch the product in research laboratories in the latter part of 2022. Lumito's product consists of a scanner […]
Successful results from a pre-study completed in collaboration with Umeå University, Sweden, shows that Lumito’s technique offers better possibilities compared with other immunohistochemical methods
A now completed pre-study, initiated at the beginning of this year in collaboration with a research group at Umeå University in Sweden led by Assistant Professor Daniel Öhlund has yielded successful results. The research group intended to identify how Lumito's UCNP (Up-Converting Nano Particles) technology could be used to improve the ability to visualise protein […]
Lumito AB publishes Quarterly Report 1, 2022
Lumito AB publishes Quarterly Report 1, 2022 Financial overview of the first quarter January 1 to March 31, 2022 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -6 430 (-6 825). Earnings per share before and after dilution amounted to SEK -0.04 (-0.08). Cash flow from operating […]
Lumito signs cooperation agreement with Optronic for 0-series production of the company’s scanner
Lumito AB and Optronic Partner pr AB have signed a cooperation agreement for the final design, industrialization and 0-series production of Lumito's first Whole Slide Imaging (WSI) scanners. The scope of the agreement is based on the delivery of 0-series production prior to Lumito's planned launch for research laboratories at the end of 2022. The […]
